Sareum (SAR) returns 700% in a year: Is this small-cap share still a good buy?

Follow us on Google News:
 Sareum (SAR) returns 700% in a year: Is this small-cap share still a good buy?
Image source: metamorworks, Shutterstock

HIGHLIGHTS

  • Saerum raised £2.37 million in June 2021 through two subscription contracts with high-net-worth individuals.
  • In July 2021, the company received approval from the US Patent and Trademark Office for the use of SDC-1802 drug molecules in the treatment of cancers. 

Sareum Holdings Plc (LON: SAR) is a drug development company that specialises in the targeted delivery of small molecule therapeutics for cancer, respiratory illnesses, and autoimmune diseases. The shares of the company have given a return of around 700% in the last one year to its shareholders.

Financial performance

Saerum raised £2.37 million in June 2021 through two subscription contracts with high-net-worth individuals. The company recorded a loss on ordinary activities of £1.6 million for the year ended 30 June 2021 compared to a £0.96 million loss in 2020 due to higher R&D expenditure associated with preclinical development.  Its cash at the bank stood at £2.7 million as of 30 June 2021 compared to £1.3 million as of 31 December 2020.

In July and August 2021, the company raised an additional £2.18 million through subscriptions of shares.

Sareum Holdings Plc returns 700% in a year                                                                            

(Data source: Refinitiv)

                                                         

Investments galore

Sareum Holdings, earlier last month obtained a funding of £1 million ($1.4 million) through a share subscription from a high-net-worth individual (HNIs) The proceeds of the funding will be used for SDC-1801 and SDC-1802 TYK2/JAK1 inhibitor drug-development programs. The investor subscribed for 12.1 million new ordinary shares at 8.25 pence per share.

SDC-1801 for Covid-19 symptoms treatment

The Covid-19 research project funded by UKRI for SDC-1801, a TYK2/JAK1 inhibitor, confirmed that the drug reduced cytokines levels associated with acute respiratory distress syndrome (ARDS) in lung cells patients affected by the SARS-CoV-2 virus. The drug also demonstrated a superior anti-inflammatory response compared to other steroids that are already in use for the treatment.

SDC-1802 for cancer immunotherapy

Sareum is engaged in the development of a design for the translational studies required to define the use of the drug molecule for optimal cancer application. In July 2021, the company received approval from the US Patent and Trademark Office to use SDC-1802 in treating cancers. 

Sareum’s share price performance

The shares of Sareum Holdings traded flat at GBX 6.90, down at 15:17 PM on 13 September 2021. The shares of the company as per the current price, have returned 695.82% in the last one year to shareholders, and its market cap stood at £232.23 million.

Conclusion:

Investors’ keen on gaining higher returns are exploring and adding pharma stocks to their portfolios. Companies engaged in cancer and COVID-19 related treatment and drug development are in high demand as investors rush to leverage from high return prospects. Pharma companies that are making profits from successful research and development initiatives are sharing profits with shareholders as well.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.